rabeprazole sodium and mycophenolate: label evidence and limits

The ACIPHEX label discusses reduced exposure to mycophenolic acid when proton-pump inhibitors are used with mycophenolate mofetil. Reduced gastric acidity can affect absorption.

Which products this evidence covers

ACIPHEX oral delayed-release rabeprazole tablets and mycophenolate mofetil (MMF).

What this finding does and does not establish

The source specifies MMF, whereas this page’s drug name is broader. The label states that the clinical relevance to organ rejection has not been established.

Supporting label passage

Intervention: Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving ACIPHEX delayed-release tablets and MMF. Use ACIPHEX delayed-release tablets with caution in transplant patients receiving MMF. See the prescribing information for other drugs dependent on gastric pH for absorption.

Read the product label on DailyMed. Section: 7 Drug Interactions — Mycophenolate mofetil. Compared label version 3, dated 2026-01-27.

How this brief was prepared

This brief uses an AI-assisted source comparison dated 2026-10-16. The label version and supporting passage were checked again on 2026-10-28. Independent clinical review has not been recorded. The comparison does not validate CDI's severity category or determine individual treatment.

Discuss your exact medicines with your pharmacist

Ask whether the cited formulation and route apply to your products and circumstances. Confirm medication decisions with your pharmacist or prescriber before changing treatment.

Check your medication list with CDI.